Yvonne McGrath
Technik-/Wissenschafts-/F&E-Leiter bei ITEOS THERAPEUTICS, INC.
Vermögen: 518 940 $ am 31.05.2024
Aktive Positionen von Yvonne McGrath
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ITEOS THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2020 | - |
Karriereverlauf von Yvonne McGrath
Ehemalige bekannte Positionen von Yvonne McGrath
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Complix NV
Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Direktor/Vorstandsmitglied | 01.05.2014 | 01.04.2020 |
Technik-/Wissenschafts-/F&E-Leiter | 01.05.2014 | 01.04.2020 | |
IMMUNOCORE HOLDINGS PLC | Corporate Officer/Principal | 01.01.2010 | 01.04.2014 |
Immunocore Ltd.
Immunocore Ltd. Pharmaceuticals: MajorHealth Technology Part of Immunocore Holdings Plc, Immunocore Ltd. is a British commercial-stage biotechnology company that develops and commercializes transformative medicines to address unmet needs in cancer, infection, and autoimmune disease. The company is based in Oxon, UK. The company has a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications, built on their proprietary soluble TCR bi-specific Immtac® platform. The company was founded in 2007, and the CEO is Bahija Jallal. | Corporate Officer/Principal | 01.01.2010 | 01.04.2014 |
Ausbildung von Yvonne McGrath
Cardiff University School of Medicine | Doctorate Degree |
Queen’S University Belfast | Undergraduate Degree |
Statistik
International
Vereinigtes Königreich | 5 |
Belgien | 2 |
Vereinigte Staaten | 2 |
Operativ
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 2 |
Director/Board Member | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ITEOS THERAPEUTICS, INC. | Health Technology |
IMMUNOCORE HOLDINGS PLC | Health Technology |
Private Unternehmen | 2 |
---|---|
Complix NV
Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Health Technology |
Immunocore Ltd.
Immunocore Ltd. Pharmaceuticals: MajorHealth Technology Part of Immunocore Holdings Plc, Immunocore Ltd. is a British commercial-stage biotechnology company that develops and commercializes transformative medicines to address unmet needs in cancer, infection, and autoimmune disease. The company is based in Oxon, UK. The company has a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications, built on their proprietary soluble TCR bi-specific Immtac® platform. The company was founded in 2007, and the CEO is Bahija Jallal. | Health Technology |
- Börse
- Insiders
- Yvonne McGrath
- Erfahrung